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Abstract
Background: The Taiwan health authority recently launched several tuberculosis (TB) control interventions, which may have
an impact on the epidemic of drug-resistant TB. We conducted a population-based antituberculosis drug resistance
surveillance program in Eastern Taiwan to measure the proportions of notified TB patients with anti-TB drug resistance and
the trend from 2004 to 2008.
Methods and Findings: All culture-positive TB patients were enrolled. Drug susceptibility testing results of the first isolate of
each TB patient in each treatment course were analyzed. In total, 2688 patients were included, of which 2176 (81.0%) were
new TB cases and 512 (19.0%) were previously treated cases. Among the 2176 new TB cases, 97 (4.5%) were retreated after
the first episode of TB treatment within the study period. The proportion of new patients with any resistance, isoniazid
resistance but not multidrug-resistant TB (resistant to at least isoniazid and rifampin, MDR-TB), and MDR-TB was 16.4%,
7.5%, and 4.0%, respectively, and that among previously treated cases was 30.9%, 7.9%, and 17.6%, respectively. The
combined proportion of any resistance decreased from 23.3% in 2004 to 14.3% in 2008, and that of MDR-TB from 11.5% to
2.4%.
Conclusions: The proportion of TB patients with drug-resistant TB in Eastern Taiwan remains substantial. However, an
effective TB control program has successfully driven the proportion of drug resistance among TB patients downward.
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Introduction
In 2007, the notification rate for tuberculosis (TB) was 63.2 per
100,000 population in Taiwan. Among all regions, Eastern
Taiwan (consisting of two counties, Hualien and Taitong) had
the highest notification rate and mortality from TB, which was105
and 7.9 per 100,000 population, respectively. World Health
Organization (WHO) and the International Union Against
Tuberculosis and Lung Disease (The Union) launched the Global
Project on Anti-tuberculosis Drug Resistance Surveillance in 1994,
based on three principles: surveillance should be based on a
samples of TB patients representative of all cases in a geographical
setting; drug resistance must be clearly distinguished according to
the history of TB treatment; and optimal laboratory performance
must be ensured through a quality-assurance program [1,2]. The
latest guideline [3] for surveillance of drug resistance in TB
indicates that surveillance, according to the International Health
Regulations adopted by the 58
th World Health Assembly, is the
systematic ongoing collection, collation and analysis of data for
public health purposes and the timely dissemination of public
health information for assessment and public health response as
necessary.A surveillancesystem based on routinedrug susceptibility
testing (DST) of all TB cases provides continuous information on
patterns and trends in anti-TB drug resistance and provides an
opportunity to monitoring outbreaks of drug-resistant TB.
No official surveillance for anti-TB drug resistance has been
conducted in Eastern Taiwan before Taiwan Centers for Disease
Control (CDC) signed a contract with the mycobacteriology
laboratory of Buddhist Tzu Chi General Hospital, which is the
only laboratory in Eastern Taiwan that performs DST for
Mycobacterium tuberculosis (M. tuberculosis). All isolates of M. tuberculosis
in Eastern Taiwan must to be sent to the mycobacteriology
laboratory of Buddhist Tzu Chi General Hospital for DST, which
forms the basis of the surveillance program in Eastern Taiwan. We
analyzed the DST results of all relevant isolates from 2004 to 2008
to determine the proportion and trend of anti-TB drug resistance
in Eastern Taiwan.
Methods
Setting and Procedures
Eastern Taiwan has a land mass of 8,144 km
2 with a population
of about 580,000. Table 1 shows the demographic profiles of the
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Mpopulation in Eastern Taiwan in 2004–2008. The number of
inhabitants who were homeless or infected with human immuno-
deficiency virus was small. One medical center, seven regional
hospitals, and 29 public health centers occur in this region. Under
the ‘‘Regional Reference Laboratory of Mycobacteriology’’
program of Taiwan CDC, sputum and clinical specimens from
suspected and confirmed tuberculosis cases identified at any health
facility in Eastern Taiwan should be sent to the mycobacteriology
laboratory of Buddhist Tzu Chi General Hospital for culture and
identification. Identification was done for all culture-positive
strains, and DST was routinely conducted for the first isolate of
every patient.
Sputum collection, processing, decontamination, culture, and
identification were performed following WHO-recommended
methods, as reported previously [4]. All pretreated specimens
were routinely inoculated into three types of media to increase
yield rates: a BACTEC MGIT 960 culture tube, a 7H11 agar
plate, and a Lowenstein-Jensen slant. Positive cultures in the
BACTEC MGIT 960 culture tube were sub-cultured using
Middlebrook 7H11 agar medium. The DST was performed using
the indirect proportion method. The critical concentrations were
0.2 mg/mL for isoniazid (INH), 1.0 mg/mL for rifampicin (RMP),
5.0 mg/mL for ethambutol (EMB), and 2.0 mg/mL for strepto-
mycin (SM), which were consistent with the WHO recommenda-
tion. Laboratory practices were not changed during the study
period. The laboratory participated in DST proficiency testing
coordinated by Taiwan CDC in 2006 and 2008 using strains
provided by the Institute of Tropical Medicine, Antwerp, Belgium
and was certified to be a quality-assured mycobacteriology
laboratory in both rounds.
Study design
All M. tuberculosis isolates recovered from notified TB cases
diagnosed at all health care facilities in Eastern Taiwan from
January 2004 to December 2008 were included in this study. A
new TB case was defined as a patient with a newly registered
episode of TB who had never been treated with anti-TB drugs for
as much as 1 month. A previously treated TB case was defined as a
patient with a newly registered episode of TB who had been
treated with anti-TB drugs for 1 month or more. Previously
treated cases included treatment after failure, treatment after
default, relapses, and other previously treated cases. Patient
treatment history was ascertained by reviewing medical records
and cross-checking with the national TB registry of Taiwan CDC.
If a patient had more than one DST result within each treatment
episode, the first DST result was included. If a new TB case, after
the first episode of treatment, was retreated because of failure,
default or relapse during the study period, the DST result of the
first isolate of the re-treatment episode was included to calculate
the proportion of drug resistance among previously treated case.
Statistical analysis
All data were entered into a computer using Microsoft Excel.
The combined proportion of drug resistance among all cases, the
proportion of resistance among new cases, and the proportion of
resistance among previously treated cases were calculated
separately. Categorical data were analyzed with the chi-square
test using SPSS 11.0 (SPSS, Inc., Chicago, IL, USA). The trends of
proportion of drug resistance in 2004–2008 were evaluated with
the Mantel-Haenszel trend test using SAS [5]. A p-value,0.05 was
regarded as statistically significant.
Ethics
This study was approved by the Institutional Review Board of
Tzu Chi General Hospital, Hualien, Taiwan. Informed consent
was waived, as the study involved routine laboratory results and
medical records, and no patient interviews were conducted.
Results
A total of 3547 tuberculosis patients were notified in 2004–2008
in Eastern Taiwan, in which 2688 were culture positive. The
current study enrolled all of the 2688 patients of culture positive
tuberculosis, accounted for 76% of all tuberculosis patients and
100% of culture positive cases in 2004–2008 in Eastern Taiwan.
Among the 2688 cases, 2176 (81.0%) were new patients and 512
(19.0%) were previously treated patients. Among the 2176 new
cases, 97 (4.5%) underwent re-treatment in 2004–2008 because of
treatment failure, default, or relapse and were also included to
calculate the proportion of anti-TB drug resistance among
previously treated cases (Figure 1). A total of 2,785 non-duplicate
isolates from 2688 TB patients were included in this study.
Susceptibility of all isolates was determined.
Of the 2785 isolates, 2240 (80.4%) were susceptible to all first-
line anti-TB drugs, 407 (14.6%) were resistant to INH, 216 (7.8%)
were resistant to RMP, 48 (1.7%) were resistant to EMB, 261
Table 1. Demographic profiles of the population in Eastern Taiwan, 2004–2008.
2004 2005 2006 2007 2008
Population, n= 589522 586241 581260 576962 573282
Sex, %
male 52.7% 52.6% 52.5% 52.3% 52.2%
female 47.3% 47.4% 47.5% 47.7% 47.8%
Age group (years), %
0–19 25.3% 24.8% 24.3% 23.9% 23.3%
20–59 59.0% 59.5% 59.7% 59.9% 60.2%
§60 15.7% 15.7% 15.9% 16.2% 16.5%
Indigenous people, % 28.4% 28.7% 28.9% 29.2% 29.4%
Homeless people, n (per 100,000 population) 166 (28.2) 109 (18.6) 80 (13.8) 53 (9.2) 26 (4.5)
HIV
a infection, n (per 100,000 population) 27 (4.6) 52 (8.9) 44 (7.6) 32 (5.5) 19 (3.3)
aHIV, human immunodeficiency virus.
doi:10.1371/journal.pone.0031531.t001
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the 2176 isolates from new cases, 1819 (83.6%) were susceptible to
all fist-line drugs; 11.6% were resistant to INH, 4.5% were
resistant to RMP, 1.1% were resistant to EMB,8.5% were resistant
to SM, and 88 (4.0%) were MDR-TB. Of the 609 isolates from
previously treated patients, 421 (69.1%) were susceptible to all
first-line drugs; 25.5% were resistant to INH, 19.5% were resistant
to RMP, 4.1% were resistant to EMB, 12.5% were resistant to
SM, and 107 (17.6%) were MDR-TB. The proportion of
resistance to any first-line drugs was significantly higher among
previously treated cases than that among new cases (p,0.005)
(Table 2).
Table 3 shows the trend of combined resistance to the four first-
line anti-TB drugs in all cases. The proportion of INH resistance,
RMP resistance, EMB resistance, and MDR decreased signifi-
cantly, but not SM resistance. The proportion of MDR-TB
decreased steadily during the study period, from 11.5% in 2004 to
2.4% in 2008. Tables 4 and 5 show the proportion of resistance
over the 5 years in new cases and previously treated cases,
respectively. The trend in the decreased proportion of resistance
was statistically significant for RMP resistance, EMB resistance,
and MDR-TB among new cases and for resistance to all first-line
drugs except SM among previously treated patients.
The downward trend of resistance among previously treated
patients was more prominent than that among new cases. Figure 2
shows that the proportion of MDR-TB among previously treated
cases was 25.9% in 2004, which decreased consistently to 5.0% in
2008 with a cumulative reduction of 80.7%. The respective figures
for that among new patients were 4.9%, 2.0% and 59.2%. Similar
findings were observed for other first-line drugs except SM.
Figure 3 shows the trends in the proportions of drug resistance
among previously treated patients and the calendar for introduc-
ing new TB control interventions in Eastern Taiwan.
Of the 216 RMP-resistant isolates, 195 (90.3%) were MDR-TB,
and the positive predictive value of RMP resistance for MDR-TB
was 90.7% (88/97) among new cases and 89.9% (107/119) among
previously treated cases.
Discussion
Anti-TB drug resistance in Eastern Taiwan has been reported
previously. The proportions of new and previously treated cases
with resistance to any first-line anti-TB drugs in 2001–2002 were
16.8% and 64.5%, respectively, and those with MDR-TB were
2.1% and 45.2%, respectively [4].These data may not be
representative of Eastern Taiwan, because isolates were mainly
collected from patients treated at a medical center. Hospital-based
studies on anti-TB drug resistance in Taiwan commonly reported
a relative high proportion of drug resistance to any first-line drug,
ranging from 30% to 52.4% [6,7].
The present study was population-based, enrolled all culture-
positive tuberculosis cases in 2004–2008 in Eastern Taiwan.The
results revealed that the proportion of anti-TB drug resistance
among notified TB cases in Eastern Taiwan remained substantial
and that the proportion of new patients with MDR-TB was higher
than the global average (4.0% vs. 2.9%). The recommended
regimen for new TB patients in Taiwan was a 2-month intensive
phase of INH, RMP, PZA, and EMB followed by a 4-month
continuation phase of INH, RMP, and EMB [8]. SM was
commonly used in the past, and the proportion of SM resistance
was as high as 15.4% in 1971 [9]. SM has not been recommended
for treating new TB patients for more than 20 years, and the
Figure 1. Flow diagram of tuberculosis subjects included in this
study.
doi:10.1371/journal.pone.0031531.g001
Table 2. Prevalence of resistance to first line anti-tuberculosis drugs in Eastern Taiwan, 2004–2008, by type of case.
Drugs
All cases
(n=2785)
New cases
(n=2176)
Previously treated
cases (n=609) p-value
Odds ratio
(95% CI)
Number (%)
Isoniazid 407 (14.6) 252 (11.6) 155 (25.5) ,0.001 2.6 (2.1–3.3)
Rifampin 216 (7.8) 97 (4.5) 119 (19.5) ,0.001 5.2 (3.9–6.9)
Ethambutol 48 (1.7) 23 (1.1) 25 (4.1) ,0.001 4.0 (2.3–7.1)
Streptomycin 261 (9.4) 185 (8.5) 76 (12.5) 0.003 1.5 (1.2–2.0)
MDR
a 195 (7.0) 88 (4.0) 107 (17.6) ,0.001 5.1 (3.8–6.8)
aMultidrug resistance, defined as resistance to at least isoniazid and rifampicin.
doi:10.1371/journal.pone.0031531.t002
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study. The proportions of resistance to INH, RMP, and EMB
among previously treated cases were significant higher than those
among new cases, with odds ratios of 2.6, 5.2, and 4.0, respectively
(Table 2). The high proportions of resistance among previously
treated patients highlights the importance of addressing the constraints
of TB control program, particularly a patient’s adherence to treatment.
The proportion of drug resistance in Eastern Taiwan decreased
significantly in 2004–2008, particularly among previously treated
patients. Similar findings were observed in recent studies
conducted at medical centers in southern and central Taiwan
[10,11]; those studies were hospital-based and study population
may not be representative, implying limitation of generalizability.
Our study revealed 79.1% cumulative reduction in the proportion
of MDR-TB among all cases in 5 years and 80.7% reduction
among previously treated cases. Although the 4
th report of Global
Project on Anti-tuberculosis Drug Resistance Surveillance dem-
onstrated decrease in the proportion of MDR-TB among all cases
Table 3. Trends of combined resistance to first-line anti-tuberculosis drugs among all cases (n=2785) in Eastern Taiwan, 2004–
2008.
Drug
a 2004 (n=532) 2005 (n=541) 2006 (n=584) 2007 (n=591) 2008 (n=537) p-value for trend
Number (%)
Any 124 (23.3) 108 (20.0) 116 (19.9) 120 (20.3) 77 (14.3) 0.002
INH 94 (17.7) 87 (16.1) 87 (14.9) 91 (15.4) 48 (8.9) ,.001
RIF 69 (13.0) 50 (9.2) 48 (8.2) 35 (5.9) 14 (2.6) ,.001
EMB 15 (2.8) 18 (3.3) 8 (1.4) 4 (0.7) 3 (0.6) ,.001
SM 63 (11.8) 42 (7.8) 54 (9.2) 56 (9.5) 46 (8.6) 0.232
MDR 61 (11.5) 45 (8.3) 42 (7.2) 34 (5.8) 13 (2.4) ,.001
aINH=isoniazid; RIF=rifampicin; EMB=ethambutol; SM=streptomycin; MDR=resistance to at least INH and RIF.
doi:10.1371/journal.pone.0031531.t003
Table 4. Trend of resistance to first-line anti-tuberculosis drugs among new cases (n=2176) in Eastern Taiwan, 2004–2008.
Drug
a 2004 (n=366) 2005 (n=404) 2006 (n=456) 2007 (n=493) 2008 (n=457) p-value for trend
Number (%)
Any 65 (17.8) 62 (15.3) 75 (16.4) 89 (18.1) 66 (14.4) 0.420
INH 41 (11.2) 49 (12.1) 54 (11.8) 68 (13.8) 40 (8.8) 0.486
RMP 21 (5.7) 21 (5.2) 22 (4.8) 23 (4.7) 10 (2.2) 0.016
EMB 5 (1.4) 10 (2.5) 3 (0.7) 3 (0.6) 2 (0.4) 0.016
SM 40 (10.9) 26 (6.4) 39 (8.6) 41 (8.3) 39 (8.5) 0.577
MDR 18 (4.9) 19 (4.7) 19 (4.2) 23 (4.7) 9 (2.0) 0.049
aINH=isoniazid; RMP=rifampin; EMB=ethambutol; SM=streptomycin; MDR=resistance to at least INH and RMP.
doi:10.1371/journal.pone.0031531.t004
Table 5. Trend of resistance to first-line anti-tuberculosis drugs among previously treated cases (n=609) in Eastern Taiwan, 2004–
2008.
Drug
a 2004 (n=166) 2005 (n=137) 2006 (n=128) 2007 (n=98) 2008 (n=80) p-value for trend
Number (%)
Any 59 (35.5) 46 (33.6) 41 (32.0) 31 (31.6) 11 (13.8) ,0.001
INH 53 (31.9) 38 (27.7) 33 (25.8) 23 (23.5) 8 (10.0) ,0.001
RMP 48 (28.9) 29 (21.2) 26 (20.3) 12 (12.2) 4 (5.0) ,0.001
EMB 10 (6.0) 8 (5.8) 5 (3.9) 1 (1.0) 1 (1.3) 0.015
SM 23 (13.9) 16 (11.7) 15 (11.7) 15 (15.3) 7 (8.8) 0.552
MDR 43 (25.9) 26 (19.0) 23 (18.0) 11 (11.2) 4 (5.0) ,0.001
aINH=isoniazid; RMP=rifampin; EMB=ethambutol; SM=streptomycin; MDR=resistance to at least INH and RMP.
doi:10.1371/journal.pone.0031531.t005
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(from 2.6% to 0.9%) and Singapore (from 0.8% to 0.3%), the
magnitude of decline in anti-TB drug resistance was not as striking
as our finding in Eastern Taiwan.
Trends in anti-tuberculosis drug resistance were regarded as an
indicator of program performance [12,13]. Several initiatives likely
contributed positively to the decline in drug-resistant TB in
Eastern Taiwan. First, the National Health Insurance (NHI)
program was launched in 1995. The NHI program is government-
run, compulsory, and inclusive, which improves access to care
among people with low socioeconomic status. The proportion of
the population insured under the NHI Program was 93% in 1996,
and has been .97% since 2002 [14,15]. Second, the ‘‘Regional
Reference Laboratory of Mycobacteriology’’ program was initiat-
ed in 2003. DST has been systematically performed for notified
tuberculosis cases, and the DST results provided guidance for
treating tuberculosis. Third, the tuberculosis case manager (TCM)
program was launched by Taiwan CDC in 2004. The TCM
program provided financial support for health care facilities to
recruit one or more TCM, depending on the number of TB
patients served. The main responsibility of the TCM is
tuberculosis case management and contacts examination. The
proportion of TB patients successfully treated at Buddhist Tzu Chi
General Hospital increased from 65.1% in 1997 to 88.4% after a
full-time TCM was recruited in 2004 [16]. Fourth, the
Department of Health of Taiwan endorsed ‘‘The Global Plan to
Stop TB 2006–2015’’, which aims to decrease the incidence of TB
by 50% in Taiwan in 10 years. The Directly Observed Therapy
(DOT) program was launched in April 2006. The proportion of
smear positive cases managed with DOT was initially 65% in
2006, and increased to 92.6% in 2007 [17]. A preliminary analysis
of data in 2006 revealed that treatment outcomes among patients
with DOT were significantly better than those without DOT,
namely patients treated with DOT had a higher proportion of
sputum conversion in 3 months (47% vs. 33%, p,0.001), higher
treatment success (75.1% vs. 51.6%, p,0.001), lower mortality
rate (13.6% vs. 37.7%, p,0.001), and fewer defaults (3.5% vs.
5.0%, p,0.01) [17]. Further, the number of previously treated
tuberculosis cases in present study has decreased from 166 in 2004
to 80 in 2008, likely due to effective case management rendering
permanent cure of TB patients .. Fifth, Taiwan CDC launched a
MDR-TB program (Taiwan MDR-TB consortium) in May 2007
to manage MDR-TB patients. A total of 225 MDR-TB patients
have been enrolled since August 2008. The proportion of patients
with a negative culture at month 18 was 87.6% among those who
were enrolled, which was 1.6- (95% confidence interval, 1.4–2.0,
p,0.0001) fold higher than those who were not enrolled [18].
The decline of drug resistance among new case was less striking
than that among previously treated cases. Transmission of drug-
resistant strains in the community prior to effective interventions
may build up a sub-population infected with drug-resistant
strains, who may develop drug-resistant tuberculosis over time.
To clarify whether there is ongoing transmission of drug resistant
tuberculosis in the community requires further researches.While
our data revealed an encouraging decline in anti-tuberculosis
drug resistance, continued surveillance on anti-tuberculosis drug
resistance is essential to monitor sustainability of the downward
trend.
The positive predictive value of RMP resistance for MDR-TB
was 90.7% among new cases and 89.9% among previously treated
cases, indicating that rifampin resistance could be used as a MDR-
TB proxy, and that rapid testing of rifampin resistance may
shorten the time for the diagnosis of MDR-TB.
In conclusion, the proportion of TB patients with drug-resistant
TB in Eastern Taiwan remains substantial. However, an effective
TB control program has successfully driven the proportion of drug
resistance among TB patients downward, which is particularly
prominent in previously treated cases. An effective TB control
program must continue in Eastern Taiwan to further reduce anti-
TB drug resistance.
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